Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,860
archived clinical trials in
Acne

The Use of Onexton in Moderate Acne Vulgaris for Patients With Skin of Color
The Use of Onexton in Moderate Acne Vulgaris for Patients With Skin of Color
Status: Enrolling
Updated:  12/31/1969
DermResearch, PLLC
mi
from
Louisville, KY
The Use of Onexton in Moderate Acne Vulgaris for Patients With Skin of Color
The Use of Onexton in Moderate Acne Vulgaris for Patients With Skin of Color
Status: Enrolling
Updated: 12/31/1969
DermResearch, PLLC
mi
from
Louisville, KY
Click here to add this to my saved trials
A Novel Method to Improve Acne Outcomes
A Novel Method for Improving Acne Outcomes
Status: Enrolling
Updated:  12/31/1969
Wake Forest University Health Sciences, Department of Dermatology
mi
from
Winston-Salem, NC
A Novel Method to Improve Acne Outcomes
A Novel Method for Improving Acne Outcomes
Status: Enrolling
Updated: 12/31/1969
Wake Forest University Health Sciences, Department of Dermatology
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.1% and RLD in the Treatment of Acne Vulgaris
A Multi-center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing TRETINOIN CREAM, 0.1% to RETIN-A® (TRETINOIN) CREAM, 0.1% and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris
Status: Enrolling
Updated:  12/31/1969
Catawba Research, LLC
mi
from
Charlotte, NC
To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.1% and RLD in the Treatment of Acne Vulgaris
A Multi-center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing TRETINOIN CREAM, 0.1% to RETIN-A® (TRETINOIN) CREAM, 0.1% and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris
Status: Enrolling
Updated: 12/31/1969
Catawba Research, LLC
mi
from
Charlotte, NC
Click here to add this to my saved trials
To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.05% and RLD in the Treatment of Acne Vulgaris
A Multi-center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing TRETINOIN CREAM, 0.05% to RETIN-A® (TRETINOIN) CREAM, 0.05% and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris
Status: Enrolling
Updated:  12/31/1969
Catawba Research, LLC
mi
from
Charlotte, NC
To Evaluate the Therapeutic Equivalence and Safety of TRETINOIN CREAM, 0.05% and RLD in the Treatment of Acne Vulgaris
A Multi-center, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Study, Comparing TRETINOIN CREAM, 0.05% to RETIN-A® (TRETINOIN) CREAM, 0.05% and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris
Status: Enrolling
Updated: 12/31/1969
Catawba Research, LLC
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Study of the Safety, Engraftment, and Action of NB01 in Adults With Moderate Acne
A Phase IB Dose Escalating Study of the Safety, Short-Term Engraftment and Action of a Singly-Applied NB01 in Adults With Moderate Acne
Status: Enrolling
Updated:  12/31/1969
Dermatology Research Associates
mi
from
Los Angeles, CA
A Study of the Safety, Engraftment, and Action of NB01 in Adults With Moderate Acne
A Phase IB Dose Escalating Study of the Safety, Short-Term Engraftment and Action of a Singly-Applied NB01 in Adults With Moderate Acne
Status: Enrolling
Updated: 12/31/1969
Dermatology Research Associates
mi
from
Los Angeles, CA
Click here to add this to my saved trials
The Use of Oracea and Epiduo Forte in Severe Acne Patients
The Use of Oracea and Epiduo Forte in Severe Acne Patients
Status: Enrolling
Updated:  12/31/1969
Skin Sciences, PLLC
mi
from
Louisville, KY
The Use of Oracea and Epiduo Forte in Severe Acne Patients
The Use of Oracea and Epiduo Forte in Severe Acne Patients
Status: Enrolling
Updated: 12/31/1969
Skin Sciences, PLLC
mi
from
Louisville, KY
Click here to add this to my saved trials
Multi-center, Randomized, Double-blind, Vehicle-controlled Efficacy and Safety Study in the Treatment of Acne Vulgaris
A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2 Arm, Parallel Group Study Comparing the Safety and Efficacy of IDP-123 Lotion and IDP-123 Vehicle Lotion in the Treatment of Acne Vulgaris
Status: Enrolling
Updated:  12/31/1969
Valeant Site 11
mi
from
San Diego, CA
Multi-center, Randomized, Double-blind, Vehicle-controlled Efficacy and Safety Study in the Treatment of Acne Vulgaris
A Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2 Arm, Parallel Group Study Comparing the Safety and Efficacy of IDP-123 Lotion and IDP-123 Vehicle Lotion in the Treatment of Acne Vulgaris
Status: Enrolling
Updated: 12/31/1969
Valeant Site 11
mi
from
San Diego, CA
Click here to add this to my saved trials
Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
An Open-Label Phase 4 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
Status: Enrolling
Updated:  12/31/1969
Kirklin Clinic
mi
from
Birmingham, AL
Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
An Open-Label Phase 4 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
Status: Enrolling
Updated: 12/31/1969
Kirklin Clinic
mi
from
Birmingham, AL
Click here to add this to my saved trials
Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
An Open-Label Phase 4 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
Status: Enrolling
Updated:  12/31/1969
Center for Dermatology Clinical Research
mi
from
Fremont, CA
Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
An Open-Label Phase 4 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
Status: Enrolling
Updated: 12/31/1969
Center for Dermatology Clinical Research
mi
from
Fremont, CA
Click here to add this to my saved trials
Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
An Open-Label Phase 4 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
Status: Enrolling
Updated:  12/31/1969
Quest Dermatology Research
mi
from
Northridge, CA
Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
An Open-Label Phase 4 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
Status: Enrolling
Updated: 12/31/1969
Quest Dermatology Research
mi
from
Northridge, CA
Click here to add this to my saved trials
Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
An Open-Label Phase 4 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
Status: Enrolling
Updated:  12/31/1969
Southern California Dermatology, Inc.
mi
from
Santa Ana, CA
Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
An Open-Label Phase 4 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
Status: Enrolling
Updated: 12/31/1969
Southern California Dermatology, Inc.
mi
from
Santa Ana, CA
Click here to add this to my saved trials
Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
An Open-Label Phase 4 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
Status: Enrolling
Updated:  12/31/1969
Redwood Family Dermatology
mi
from
Santa Rosa, CA
Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
An Open-Label Phase 4 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
Status: Enrolling
Updated: 12/31/1969
Redwood Family Dermatology
mi
from
Santa Rosa, CA
Click here to add this to my saved trials
Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
An Open-Label Phase 4 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
Status: Enrolling
Updated:  12/31/1969
The Center for Clinical and Cosmetic Research
mi
from
Aventura, FL
Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
An Open-Label Phase 4 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
Status: Enrolling
Updated: 12/31/1969
The Center for Clinical and Cosmetic Research
mi
from
Aventura, FL
Click here to add this to my saved trials
Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
An Open-Label Phase 4 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
Status: Enrolling
Updated:  12/31/1969
Baumann Cosmetic and Research Institute
mi
from
Miami Beach, FL
Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
An Open-Label Phase 4 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
Status: Enrolling
Updated: 12/31/1969
Baumann Cosmetic and Research Institute
mi
from
Miami Beach, FL
Click here to add this to my saved trials
Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
An Open-Label Phase 4 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
Status: Enrolling
Updated:  12/31/1969
DermResearch, PLLC
mi
from
Louisville, KY
Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
An Open-Label Phase 4 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
Status: Enrolling
Updated: 12/31/1969
DermResearch, PLLC
mi
from
Louisville, KY
Click here to add this to my saved trials
Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
An Open-Label Phase 4 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
Status: Enrolling
Updated:  12/31/1969
Hamzavi Dermatology
mi
from
Fort Gratiot, MI
Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
An Open-Label Phase 4 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
Status: Enrolling
Updated: 12/31/1969
Hamzavi Dermatology
mi
from
Fort Gratiot, MI
Click here to add this to my saved trials
Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
An Open-Label Phase 4 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
Status: Enrolling
Updated:  12/31/1969
Saint Louis University Dermatology
mi
from
Saint Louis, MO
Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
An Open-Label Phase 4 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
Status: Enrolling
Updated: 12/31/1969
Saint Louis University Dermatology
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
An Open-Label Phase 4 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
Status: Enrolling
Updated:  12/31/1969
Skin Specialists, PC
mi
from
Omaha, NE
Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
An Open-Label Phase 4 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
Status: Enrolling
Updated: 12/31/1969
Skin Specialists, PC
mi
from
Omaha, NE
Click here to add this to my saved trials
Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
An Open-Label Phase 4 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
Status: Enrolling
Updated:  12/31/1969
Skin Specialty Dermatology
mi
from
New York, NY
Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
An Open-Label Phase 4 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
Status: Enrolling
Updated: 12/31/1969
Skin Specialty Dermatology
mi
from
New York, NY
Click here to add this to my saved trials
Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
An Open-Label Phase 4 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
Status: Enrolling
Updated:  12/31/1969
Health Sciences/Department of Dermatology
mi
from
Winston-Salem, NC
Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
An Open-Label Phase 4 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
Status: Enrolling
Updated: 12/31/1969
Health Sciences/Department of Dermatology
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
An Open-Label Phase 4 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
Status: Enrolling
Updated:  12/31/1969
KGL Skin Study Center
mi
from
Broomall, PA
Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
An Open-Label Phase 4 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
Status: Enrolling
Updated: 12/31/1969
KGL Skin Study Center
mi
from
Broomall, PA
Click here to add this to my saved trials
Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
An Open-Label Phase 4 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
Status: Enrolling
Updated:  12/31/1969
Department of Dermatology, UPCII
mi
from
Hershey, PA
Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
An Open-Label Phase 4 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
Status: Enrolling
Updated: 12/31/1969
Department of Dermatology, UPCII
mi
from
Hershey, PA
Click here to add this to my saved trials
Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
An Open-Label Phase 4 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
Status: Enrolling
Updated:  12/31/1969
Arlington Research Center
mi
from
Arlington, TX
Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
An Open-Label Phase 4 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
Status: Enrolling
Updated: 12/31/1969
Arlington Research Center
mi
from
Arlington, TX
Click here to add this to my saved trials
Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
An Open-Label Phase 4 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
Status: Enrolling
Updated:  12/31/1969
DermResearch, Inc.
mi
from
Austin, TX
Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
An Open-Label Phase 4 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
Status: Enrolling
Updated: 12/31/1969
DermResearch, Inc.
mi
from
Austin, TX
Click here to add this to my saved trials
Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
An Open-Label Phase 4 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
Status: Enrolling
Updated:  12/31/1969
University of Texas Medical School in Houston
mi
from
Houston, TX
Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
An Open-Label Phase 4 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
Status: Enrolling
Updated: 12/31/1969
University of Texas Medical School in Houston
mi
from
Houston, TX
Click here to add this to my saved trials
Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
An Open-Label Phase 4 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
Status: Enrolling
Updated:  12/31/1969
Austin Institute for Clinical Research, Inc.
mi
from
Pflugerville, TX
Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
An Open-Label Phase 4 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
Status: Enrolling
Updated: 12/31/1969
Austin Institute for Clinical Research, Inc.
mi
from
Pflugerville, TX
Click here to add this to my saved trials
Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
An Open-Label Phase 4 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
Status: Enrolling
Updated:  12/31/1969
Premier Clinical Research
mi
from
Spokane, WA
Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
An Open-Label Phase 4 Safety and Efficacy Trial of ACZONE (Dapsone) Gel, 7.5% in 9 to 11 Year-Old Patients With Acne Vulgaris
Status: Enrolling
Updated: 12/31/1969
Premier Clinical Research
mi
from
Spokane, WA
Click here to add this to my saved trials
A Study of the Safety and Efficacy of DFD-03 for the Treatment of Acne Vulgaris
A Multicenter, Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Study of the Safety and Efficacy of DFD-03 Lotion in the Treatment of Acne Vulgaris for 12 Weeks
Status: Enrolling
Updated:  12/31/1969
Dr. Seemal
mi
from
Plano, TX
A Study of the Safety and Efficacy of DFD-03 for the Treatment of Acne Vulgaris
A Multicenter, Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled Study of the Safety and Efficacy of DFD-03 Lotion in the Treatment of Acne Vulgaris for 12 Weeks
Status: Enrolling
Updated: 12/31/1969
Dr. Seemal
mi
from
Plano, TX
Click here to add this to my saved trials
Safety and Efficacy of the Use of Botox on Acne
Double-Blind, Randomized, Placebo-Controlled Study to Determine the Safety and the Efficacy of Using Botulinum Neurotoxin Type A Injections for Subjects With Mild to Moderate Acne Vulgaris
Status: Enrolling
Updated:  12/31/1969
DeNova Research
mi
from
Chicago, IL
Safety and Efficacy of the Use of Botox on Acne
Double-Blind, Randomized, Placebo-Controlled Study to Determine the Safety and the Efficacy of Using Botulinum Neurotoxin Type A Injections for Subjects With Mild to Moderate Acne Vulgaris
Status: Enrolling
Updated: 12/31/1969
DeNova Research
mi
from
Chicago, IL
Click here to add this to my saved trials
Teledermatology and Modulation of Antibiotic Dose in Acne Vulgaris
Teledermatology and Modulation of Antibiotic Dose in Acne Vulgaris
Status: Enrolling
Updated:  12/31/1969
UC Davis Department of Dermatology, Clinical Trials Unit
mi
from
Sacramento, CA
Teledermatology and Modulation of Antibiotic Dose in Acne Vulgaris
Teledermatology and Modulation of Antibiotic Dose in Acne Vulgaris
Status: Enrolling
Updated: 12/31/1969
UC Davis Department of Dermatology, Clinical Trials Unit
mi
from
Sacramento, CA
Click here to add this to my saved trials
A Bioavailability Study of DFD-03 (Tazarotene, Lotion 0.1 % ) Compared to Tazorac® (Tazarotene), 0.1% in Patients With Moderate Acne Vulgaris
A Randomized, Open-Label, Multiple Dose, Bioavailability Study of DFD-03 (Tazarotene Lotion, 0.1 % ) Dosed Twice Daily Compared to Once Daily Tazorac® (Tazarotene) Cream, 0.1% in Patients With Moderate Acne Vulgaris
Status: Enrolling
Updated:  12/31/1969
Dr. DuBois
mi
from
Austin, TX
A Bioavailability Study of DFD-03 (Tazarotene, Lotion 0.1 % ) Compared to Tazorac® (Tazarotene), 0.1% in Patients With Moderate Acne Vulgaris
A Randomized, Open-Label, Multiple Dose, Bioavailability Study of DFD-03 (Tazarotene Lotion, 0.1 % ) Dosed Twice Daily Compared to Once Daily Tazorac® (Tazarotene) Cream, 0.1% in Patients With Moderate Acne Vulgaris
Status: Enrolling
Updated: 12/31/1969
Dr. DuBois
mi
from
Austin, TX
Click here to add this to my saved trials
A Bioavailability Study of DFD-03 (Tazarotene, Lotion 0.1 % ) Compared to Tazorac® (Tazarotene), 0.1% in Patients With Moderate Acne Vulgaris
A Randomized, Open-Label, Multiple Dose, Bioavailability Study of DFD-03 (Tazarotene Lotion, 0.1 % ) Dosed Twice Daily Compared to Once Daily Tazorac® (Tazarotene) Cream, 0.1% in Patients With Moderate Acne Vulgaris
Status: Enrolling
Updated:  12/31/1969
Dr. Jones
mi
from
Austin, TX
A Bioavailability Study of DFD-03 (Tazarotene, Lotion 0.1 % ) Compared to Tazorac® (Tazarotene), 0.1% in Patients With Moderate Acne Vulgaris
A Randomized, Open-Label, Multiple Dose, Bioavailability Study of DFD-03 (Tazarotene Lotion, 0.1 % ) Dosed Twice Daily Compared to Once Daily Tazorac® (Tazarotene) Cream, 0.1% in Patients With Moderate Acne Vulgaris
Status: Enrolling
Updated: 12/31/1969
Dr. Jones
mi
from
Austin, TX
Click here to add this to my saved trials
Subject Reported Outcomes With Use of Adapalene 0.3% - Benzoyl Peroxide (BPO) 2.5% in Dark Skin Acne
Subject Reported Outcomes With Use of Adapalene 0.3% - Benzoyl Peroxide 2.5% in Moderate to Severe Acne in Dark Skin Phototype Subjects
Status: Enrolling
Updated:  12/31/1969
DermResearch, Inc.
mi
from
Austin, TX
Subject Reported Outcomes With Use of Adapalene 0.3% - Benzoyl Peroxide (BPO) 2.5% in Dark Skin Acne
Subject Reported Outcomes With Use of Adapalene 0.3% - Benzoyl Peroxide 2.5% in Moderate to Severe Acne in Dark Skin Phototype Subjects
Status: Enrolling
Updated: 12/31/1969
DermResearch, Inc.
mi
from
Austin, TX
Click here to add this to my saved trials
Subject Reported Outcomes With Use of Adapalene 0.3% - Benzoyl Peroxide (BPO) 2.5% in Dark Skin Acne
Subject Reported Outcomes With Use of Adapalene 0.3% - Benzoyl Peroxide 2.5% in Moderate to Severe Acne in Dark Skin Phototype Subjects
Status: Enrolling
Updated:  12/31/1969
CIDP
mi
from
Phoenix,
Subject Reported Outcomes With Use of Adapalene 0.3% - Benzoyl Peroxide (BPO) 2.5% in Dark Skin Acne
Subject Reported Outcomes With Use of Adapalene 0.3% - Benzoyl Peroxide 2.5% in Moderate to Severe Acne in Dark Skin Phototype Subjects
Status: Enrolling
Updated: 12/31/1969
CIDP
mi
from
Phoenix,
Click here to add this to my saved trials
Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris
A Multi-Center, Double-Blind, Randomized, Three-Arm, Placebo Controlled, Parallel-Group Study, Comparing Adapalene Gel 0.3% To Differin® Gel 0.3% And Both Active Treatments To A Placebo Control In The Treatment Of Acne Vulgaris
Status: Enrolling
Updated:  12/31/1969
Unison Center for Clinical Trials
mi
from
Sherman Oaks, CA
Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris
A Multi-Center, Double-Blind, Randomized, Three-Arm, Placebo Controlled, Parallel-Group Study, Comparing Adapalene Gel 0.3% To Differin® Gel 0.3% And Both Active Treatments To A Placebo Control In The Treatment Of Acne Vulgaris
Status: Enrolling
Updated: 12/31/1969
Unison Center for Clinical Trials
mi
from
Sherman Oaks, CA
Click here to add this to my saved trials
Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris
A Multi-Center, Double-Blind, Randomized, Three-Arm, Placebo Controlled, Parallel-Group Study, Comparing Adapalene Gel 0.3% To Differin® Gel 0.3% And Both Active Treatments To A Placebo Control In The Treatment Of Acne Vulgaris
Status: Enrolling
Updated:  12/31/1969
Moore Clinical Research Institute, Inc.
mi
from
Brandon, FL
Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris
A Multi-Center, Double-Blind, Randomized, Three-Arm, Placebo Controlled, Parallel-Group Study, Comparing Adapalene Gel 0.3% To Differin® Gel 0.3% And Both Active Treatments To A Placebo Control In The Treatment Of Acne Vulgaris
Status: Enrolling
Updated: 12/31/1969
Moore Clinical Research Institute, Inc.
mi
from
Brandon, FL
Click here to add this to my saved trials
Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris
A Multi-Center, Double-Blind, Randomized, Three-Arm, Placebo Controlled, Parallel-Group Study, Comparing Adapalene Gel 0.3% To Differin® Gel 0.3% And Both Active Treatments To A Placebo Control In The Treatment Of Acne Vulgaris
Status: Enrolling
Updated:  12/31/1969
FXM Research Corp.
mi
from
Miami, FL
Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris
A Multi-Center, Double-Blind, Randomized, Three-Arm, Placebo Controlled, Parallel-Group Study, Comparing Adapalene Gel 0.3% To Differin® Gel 0.3% And Both Active Treatments To A Placebo Control In The Treatment Of Acne Vulgaris
Status: Enrolling
Updated: 12/31/1969
FXM Research Corp.
mi
from
Miami, FL
Click here to add this to my saved trials
Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris
A Multi-Center, Double-Blind, Randomized, Three-Arm, Placebo Controlled, Parallel-Group Study, Comparing Adapalene Gel 0.3% To Differin® Gel 0.3% And Both Active Treatments To A Placebo Control In The Treatment Of Acne Vulgaris
Status: Enrolling
Updated:  12/31/1969
FXM Research Miramar
mi
from
Miramar, FL
Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris
A Multi-Center, Double-Blind, Randomized, Three-Arm, Placebo Controlled, Parallel-Group Study, Comparing Adapalene Gel 0.3% To Differin® Gel 0.3% And Both Active Treatments To A Placebo Control In The Treatment Of Acne Vulgaris
Status: Enrolling
Updated: 12/31/1969
FXM Research Miramar
mi
from
Miramar, FL
Click here to add this to my saved trials
Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris
A Multi-Center, Double-Blind, Randomized, Three-Arm, Placebo Controlled, Parallel-Group Study, Comparing Adapalene Gel 0.3% To Differin® Gel 0.3% And Both Active Treatments To A Placebo Control In The Treatment Of Acne Vulgaris
Status: Enrolling
Updated:  12/31/1969
Moore Clinical Research Institute, Inc.
mi
from
Tampa, FL
Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris
A Multi-Center, Double-Blind, Randomized, Three-Arm, Placebo Controlled, Parallel-Group Study, Comparing Adapalene Gel 0.3% To Differin® Gel 0.3% And Both Active Treatments To A Placebo Control In The Treatment Of Acne Vulgaris
Status: Enrolling
Updated: 12/31/1969
Moore Clinical Research Institute, Inc.
mi
from
Tampa, FL
Click here to add this to my saved trials
Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris
A Multi-Center, Double-Blind, Randomized, Three-Arm, Placebo Controlled, Parallel-Group Study, Comparing Adapalene Gel 0.3% To Differin® Gel 0.3% And Both Active Treatments To A Placebo Control In The Treatment Of Acne Vulgaris
Status: Enrolling
Updated:  12/31/1969
Dermatology Consulting Services
mi
from
High Point, NC
Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris
A Multi-Center, Double-Blind, Randomized, Three-Arm, Placebo Controlled, Parallel-Group Study, Comparing Adapalene Gel 0.3% To Differin® Gel 0.3% And Both Active Treatments To A Placebo Control In The Treatment Of Acne Vulgaris
Status: Enrolling
Updated: 12/31/1969
Dermatology Consulting Services
mi
from
High Point, NC
Click here to add this to my saved trials
Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris
A Multi-Center, Double-Blind, Randomized, Three-Arm, Placebo Controlled, Parallel-Group Study, Comparing Adapalene Gel 0.3% To Differin® Gel 0.3% And Both Active Treatments To A Placebo Control In The Treatment Of Acne Vulgaris
Status: Enrolling
Updated:  12/31/1969
3A Research, LLC
mi
from
El Paso, TX
Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris
A Multi-Center, Double-Blind, Randomized, Three-Arm, Placebo Controlled, Parallel-Group Study, Comparing Adapalene Gel 0.3% To Differin® Gel 0.3% And Both Active Treatments To A Placebo Control In The Treatment Of Acne Vulgaris
Status: Enrolling
Updated: 12/31/1969
3A Research, LLC
mi
from
El Paso, TX
Click here to add this to my saved trials
Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris
A Multi-Center, Double-Blind, Randomized, Three-Arm, Placebo Controlled, Parallel-Group Study, Comparing Adapalene Gel 0.3% To Differin® Gel 0.3% And Both Active Treatments To A Placebo Control In The Treatment Of Acne Vulgaris
Status: Enrolling
Updated:  12/31/1969
FXM Research International
mi
from
Belize City,
Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris
A Multi-Center, Double-Blind, Randomized, Three-Arm, Placebo Controlled, Parallel-Group Study, Comparing Adapalene Gel 0.3% To Differin® Gel 0.3% And Both Active Treatments To A Placebo Control In The Treatment Of Acne Vulgaris
Status: Enrolling
Updated: 12/31/1969
FXM Research International
mi
from
Belize City,
Click here to add this to my saved trials
A Phase 1 Study Assessing Local Cutaneous Effects of SB204
A Phase 1, Single-Center, Split-Face Study Assessing Local Cutaneous Effects After Application of SB204 2% and SB204 4% in Healthy Volunteers
Status: Enrolling
Updated:  12/31/1969
KGL, Inc
mi
from
Broomall, PA
A Phase 1 Study Assessing Local Cutaneous Effects of SB204
A Phase 1, Single-Center, Split-Face Study Assessing Local Cutaneous Effects After Application of SB204 2% and SB204 4% in Healthy Volunteers
Status: Enrolling
Updated: 12/31/1969
KGL, Inc
mi
from
Broomall, PA
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Tolerance of 2 Acne Treatment Regimens on Subjects With Mild to Moderate Acne
A Multi-Center, Evaluator Blinded, Randomized Clinical Study to Evaluate the Efficacy and Tolerance of Two Acne Treatment Regimens on Subjects With Mild to Moderate Acne Vulgaris
Status: Enrolling
Updated:  12/31/1969
Academic Dermatology Associates
mi
from
Albuquerque, NM
A Study to Evaluate the Efficacy and Tolerance of 2 Acne Treatment Regimens on Subjects With Mild to Moderate Acne
A Multi-Center, Evaluator Blinded, Randomized Clinical Study to Evaluate the Efficacy and Tolerance of Two Acne Treatment Regimens on Subjects With Mild to Moderate Acne Vulgaris
Status: Enrolling
Updated: 12/31/1969
Academic Dermatology Associates
mi
from
Albuquerque, NM
Click here to add this to my saved trials
A Study to Evaluate the Efficacy and Tolerance of 2 Acne Treatment Regimens on Subjects With Mild to Moderate Acne
A Multi-Center, Evaluator Blinded, Randomized Clinical Study to Evaluate the Efficacy and Tolerance of Two Acne Treatment Regimens on Subjects With Mild to Moderate Acne Vulgaris
Status: Enrolling
Updated:  12/31/1969
Thomas J. Stephens and Associates, Inc.
mi
from
Richardson, TX
A Study to Evaluate the Efficacy and Tolerance of 2 Acne Treatment Regimens on Subjects With Mild to Moderate Acne
A Multi-Center, Evaluator Blinded, Randomized Clinical Study to Evaluate the Efficacy and Tolerance of Two Acne Treatment Regimens on Subjects With Mild to Moderate Acne Vulgaris
Status: Enrolling
Updated: 12/31/1969
Thomas J. Stephens and Associates, Inc.
mi
from
Richardson, TX
Click here to add this to my saved trials
A Study Comparing Two Topicals in the Treatment of Acne Vulgaris
A Randomized, Evaluator-Blinded, Bilateral Comparison Study of Two Topicals in the Treatment of Subjects With Acne Vulgaris
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
San Diego, CA
A Study Comparing Two Topicals in the Treatment of Acne Vulgaris
A Randomized, Evaluator-Blinded, Bilateral Comparison Study of Two Topicals in the Treatment of Subjects With Acne Vulgaris
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
A Phase 1 Study Evaluating Safety and Tolerability of NVN1000 Gel
A Phase 1, Multiple-dose, Evaluator-blind, Randomized, Parallel Group Study Evaluating the Safety and Cutaneous Tolerability of SB204 (NVN1000 Gel) in Healthy Volunteers
Status: Enrolling
Updated:  12/31/1969
KGL, Inc
mi
from
Broomall, PA
A Phase 1 Study Evaluating Safety and Tolerability of NVN1000 Gel
A Phase 1, Multiple-dose, Evaluator-blind, Randomized, Parallel Group Study Evaluating the Safety and Cutaneous Tolerability of SB204 (NVN1000 Gel) in Healthy Volunteers
Status: Enrolling
Updated: 12/31/1969
KGL, Inc
mi
from
Broomall, PA
Click here to add this to my saved trials
An Evaluation of the Adrenal Suppression Potential and PK of CB-03-01 Cream in Pediatric Patients With Acne Vulgaris
An Open Label Evaluation of the Adrenal Suppression Potential and Trough Plasma Concentrations of Cortexolone 17α-Propionate (CB-03-01) Cream Applied Every 12 Hours for Two Weeks in Subjects 9 to <12 Years of Age With Acne Vulgaris
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Fort Smith, AR
An Evaluation of the Adrenal Suppression Potential and PK of CB-03-01 Cream in Pediatric Patients With Acne Vulgaris
An Open Label Evaluation of the Adrenal Suppression Potential and Trough Plasma Concentrations of Cortexolone 17α-Propionate (CB-03-01) Cream Applied Every 12 Hours for Two Weeks in Subjects 9 to <12 Years of Age With Acne Vulgaris
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Fort Smith, AR
Click here to add this to my saved trials
An Evaluation of the Adrenal Suppression Potential and PK of CB-03-01 Cream in Pediatric Patients With Acne Vulgaris
An Open Label Evaluation of the Adrenal Suppression Potential and Trough Plasma Concentrations of Cortexolone 17α-Propionate (CB-03-01) Cream Applied Every 12 Hours for Two Weeks in Subjects 9 to <12 Years of Age With Acne Vulgaris
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
San Diego, CA
An Evaluation of the Adrenal Suppression Potential and PK of CB-03-01 Cream in Pediatric Patients With Acne Vulgaris
An Open Label Evaluation of the Adrenal Suppression Potential and Trough Plasma Concentrations of Cortexolone 17α-Propionate (CB-03-01) Cream Applied Every 12 Hours for Two Weeks in Subjects 9 to <12 Years of Age With Acne Vulgaris
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
An Evaluation of the Adrenal Suppression Potential and PK of CB-03-01 Cream in Pediatric Patients With Acne Vulgaris
An Open Label Evaluation of the Adrenal Suppression Potential and Trough Plasma Concentrations of Cortexolone 17α-Propionate (CB-03-01) Cream Applied Every 12 Hours for Two Weeks in Subjects 9 to <12 Years of Age With Acne Vulgaris
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Houston, TX
An Evaluation of the Adrenal Suppression Potential and PK of CB-03-01 Cream in Pediatric Patients With Acne Vulgaris
An Open Label Evaluation of the Adrenal Suppression Potential and Trough Plasma Concentrations of Cortexolone 17α-Propionate (CB-03-01) Cream Applied Every 12 Hours for Two Weeks in Subjects 9 to <12 Years of Age With Acne Vulgaris
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials